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Abstract
Interstitial cystitis/painful bladder syndrome (IC/PBS) is a heterogeneous 
syndrome characterized by bladder pain and associated with frequency and 
nocturia. Recent findings have proposed several pathophysiological mecha-
nisms including epithelial dysfunction, activation of mast cells, neurogenic 
inflammation, autoimmunity and occult infection. The human bladder 
urothelium and urothelial cells play an important role in the normal defense 
mechanism. One of the most common findings in IC/PBS patients is denu-
dation or thinning of the bladder epithelium, suggesting an altered regula-
tion of urothelial homeostasis. Urine from patients with IC/PBS has been 
shown to inhibit urothelial proliferation through antiproliferative factor (APF). 
In urine samples of IC/PBS patients, significant increases in APF, decreases 
in heparin-binding epidermal growth factor (HB-EGF) and increased levels 
of EGF were discovered. APF expressed by the urothelial cells induces 
increased permeability in cell culture, and regulates expression of other 
cytokines, including upregulation of HB-EGF and downregulation of EGF. 
These cytokine abnormalities were also related to increases in purinergic 
signaling, which mediates increased bladder sensation. Abnormal expres-
sion of uroplakin, chondroitin sulfate and tight junctional protein zonula 
occludens-1 (ZO-1) strongly suggests abnormal differentiation in bladders 
with IC/PBS, whereas elevated E-cadherin expression may represent an 
adaptation to increased bladder permeability. The epithelial damage may 
precede the other histopathologic findings in the bladder wall. A local inflam-
matory process might be induced through the afferent and efferent nerves 
in the suburothelial interstitial cellular network which integrate the transmis-
sion of signals from the urothelium to the detrusor muscles in the bladder 
wall. Investigation of the relationship between chronic inflammation and 
urothelial dysfunction such as urothelial apoptosis, expression of junctional 
protein and inflammatory reactions in the suburothelium might demonstrate 
this hypothesis. [Tzu Chi Med J 2009;21(2):103–109]
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1. Introduction
Interstitial cystitis/painful bladder syndrome (IC/PBS) 
is a chronic bladder condition seen mainly in women 
(10:1 female to male). It is characterized by bladder 
pain, frequency and nocturia. There is no clear defini-
tion of IC/PBS as the clinical symptoms and histology 
are not specific. The diagnosis of IC/PBS can only be 
based on a combination of a thorough patient history, 
sterile and cytologically negative urine, cystoscopic hy-
drodistention under anesthesia and bladder biopsies. 
Many different etiologies have been proposed, includ-
ing: (1) a post-infection autoimmune process; (2) mast 
cell activation induced by inflammation, toxins or 
stress; (3) urothelial dysfunction and increased perme-
ability of the urothelium; and (4) neurogenic inflam-
mation. However, none of these etiologies has been 
definitely proven, and therefore, no single treatment 
has been reported to have long-term effects in eradicat-
ing symptoms of this mysterious bladder disorder [1].
2. Chronic inflammation in IC/PBS
The cause of IC/PBS has been considered to result 
from long-standing inflammation of the bladder. 
Bladder histological analysis shows infiltrates of mast 
cells, eosinophilic leukocytes and T-lymphocytes. This 
suggests that the disease is mediated by the immune 
system [2]. However, the triggering factor that leads 
to disease is still unknown. In previous reports, the 
histological evidence has shown several marked 
changes in various tissue elements. First, abnormal 
behavior of urothelial cells disrupts the permeability 
barrier. Second, vascular lesions include endothelial 
cell injury and suggest a slow microcirculation. Third, 
neural changes include a combination of degenera-
tive and regenerative features [3,4].
Previous reports indicate that the urothelium plays 
a pivotal role as a barrier between urine and its 
solutes and the underlying bladder. Bladder surface 
mucus is a critical component of this function [5–7]. 
The biologic activity of mucus that imparts this bar-
rier function is generated by the highly anionic poly-
saccharide components (glycosaminoglycans), which 
are extremely hydrophilic and trap water at the outer 
layer of the umbrella cell. In patients with IC/PBS, 
disruption of the urothelial barrier may initiate a cas-
cade of events in the bladder, leading to symptoms 
and disease. Specifically, urothelial dysfunction leads 
to the migration of urinary solutes, in particular, po-
tassium, which depolarizes nerves and muscles and 
causes tissue injury [8,9]. Consequently, it is impera-
tive to understand the biologic effects by which the 
urothelium changes its growth behavior and the ex-
pression pattern of signal transduction molecules 
under these effects.
The chronic pain symptomatology in IC/PBS may 
also be due to central nervous system sensitization 
and persisting abnormality or activation of the afferent 
sensory system in the urinary bladder [10]. Increased 
central c-fos expression has been demonstrated in 
animal models of neurogenic detrusor overactivity and 
chronic inflammation. Elimination of rat spinal neu-
rons expressing neurokinin 1 receptors reduces blad-
der overactivity and spinal c-fos expression induced 
by bladder irritation [11,12]. If the neurogenic inflam-
mation in the dorsal root ganglia can be eliminated 
gradually through intravesical treatment, the visceral 
pain in IC/PBS can thus be relieved.
Recent findings have proposed several pathophysi-
ological mechanisms, including epithelial dysfunction, 
activation of mast cells, neurogenic inflammation, 
autoimmunity and occult infection. Therefore, treat-
ments targeting these pathophysiologies have been 
investigated [13]. One of the most common findings 
in bladder mucosal biopsies from IC/PBS patients is 
denudation or thinning of the bladder epithelium, sug-
gesting an altered regulation of urothelial homeosta-
sis. Other bladder abnormalities include increased 
nerve fiber density and inflammatory cell infiltration. 
Previous reports on bladder biopsies of patients with 
IC/PBS have confirmed the involvement and presence 
of eosinophils, macrophages in the urothelium and 
mast cells in the detrusor. Involvement of eosinophils 
is also supported by urine cytology showing increased 
urinary eosinophil cationic protein in the urine of pa-
tients with IC/PBS [14,15]. Mast cells have been consid-
ered as crucial effector cells for the immune response 
implicated in the pathogenesis of IC/PBS [2].
3. Biomarkers for IC/PBS in the bladder 
and urine
IC/PBS was found to be associated with increased 
urinary adenosine triphosphate (ATP) and increased 
stretch-activated ATP release by bladder urothelial 
cells, suggesting augmented purinergic signaling in 
the bladder, which could be blocked by suramin and 
heparin-binding epidermal growth factor-like growth 
hormone (HB-EGF) [16]. Single-cell electrophysiological 
studies revealed that the strong inward rectifying potas-
sium current with conductance of the Kir2.1 channel 
was significantly reduced in IC/PBS bladder urothelial 
cells. Epidermal growth factor (EGF) caused a dose-
dependent decrease in the inward potassium current. 
Treatment of IC-bladder urothelial cells (BUC) with 
HB-EGF significantly increased the current. Changes 
in BUC membrane potassium conductance caused by 
altered levels of EGF and HB-EGF may play a role in 
the pathophysiology of IC/PBS [17].
Antiproliferative factor (APF) is a small glycoprotein 
made specifically by bladder epithelial cells in patients 
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with IC/PBS that induces changes in expression of 
certain epithelial cell proteins and profoundly inhibits 
cell growth. APF may affect the increased permeability 
and decreased tight junction formation of bladder epi-
thelial cells and contribute to the urothelial leak and 
bladder pain symptoms seen in IC/PBS [18]. In urine 
samples of patients with IC/PBS, significant increases 
in APF, decreases in HB-EGF and increased levels of 
EGF were discovered [19]. Urine from patients with 
IC/PBS has been shown to inhibit urothelial prolifera-
tion through APF and to contain decreased levels of 
HB-EGF compared to controls. Hydrodistention of blad-
ders with IC/PBS significantly increased urinary HB-EGF 
toward control values and decreased urinary APF ac-
tivity, but APF levels at 2 weeks after hydrodistention 
were still significantly higher than in controls [20].
Several previous studies reported the discovery of 
APF which is made uniquely by bladder epithelial cells 
from patients with IC/PBS and profoundly inhibits 
normal bladder epithelial cell growth [21]. Microarray 
analysis indicated that APF can also induce changes 
in the pattern of cellular gene expression toward a 
more differentiated phenotype. Identification of this 
factor is therefore important for determining its poten-
tial role in the pathogenesis of IC/PBS and establish-
ing its utility as a biomarker for this disease [19]. 
Previous results indicate that APF treatment causes 
significant increases in the paracellular permeability 
of normal bladder epithelial cell monolayers and the 
attenuation of tight junctions compared to mock 
APF, similar to changes seen in IC/PBS cells. Because 
of its apparent effects on bladder epithelial cell tight 
junctions and paracellular permeability in vitro, APF 
may contribute to the leakiness of the bladder epi-
thelial barrier seen in IC/PBS [22].
The human bladder urothelium and urothelial cells 
play an important role in the normal defense mecha-
nism. APF expressed by the urothelial cells induces 
increased permeability in cell culture, and regulates 
expression of other cytokines, including upregulation 
of HB-EGF and downregulation of EGF. These cytokine 
abnormalities are also related to increases in purin-
ergic signaling, which mediates increased bladder 
sensation. Alterations of uroplakins, a glycoprotein 
expressed only in the apical urothelial cells, may result 
in bladder symptoms related to increased permeabil-
ity or decreased protective function [23].
4. Urothelial dysfunction in IC/PBS
Studies of urothelial differentiation in IC/PBS also 
demonstrated that the acquisition of a transitional 
cell morphology occurred in some IC-derived cell lines, 
suggesting that a subset of patients with IC/PBS 
might have a failure of urothelial cytodifferentiation, 
which might contribute to the disease and bladder 
dysfunction [5]. Abnormal expression of molecular 
markers has been found in IC/PBS bladder biopsies. 
Abnormal expression of uroplakin, chondroitin sul-
fate and tight junctional protein zonula occludens-1 
(ZO-1) strongly suggests abnormal differentiation in 
bladders with IC/PBS, whereas elevated E-cadherin 
expression may represent an adaptation to increased 
bladder permeability [24].
Ki-67 is a commercially available monoclonal anti-
body that reacts with a nuclear antigen expressed in 
proliferating cells but not in quiescent cells. Expres-
sion of this antigen occurs preferentially during the 
late G1, S, G2, and M phases of the cell cycle, while 
in cells in the G0 phase the antigen cannot be de-
tected [25]. To confirm the results of a TUNEL stain, 
we compared the ratio of proliferating and apoptotic 
cells in a pathologic assay (Fig. 1). The preliminary 
data showed that Ki-67 positive cells are rare in IC/
PBS patients compared with controls (Fig. 2). These 
results are consistent with previous reports.
Vascular endothelial growth factor (VEGF), which 
plays a key role in bladder inflammation, is closely 
associated with the vascular alterations observed in 
patients with IC/PBS. In addition, recent findings indi-
cate that VEGF-Rs and co-receptors (neuropilins; NRP) 
are strongly expressed in both the human bladder 
urothelium and in a human bladder cancer cell line 
(J82) and that the expression of NRP2 and VEGF-R1 is 
significantly downregulated in subjects with IC/PBS 
compared with control subjects [4]. These results 
suggest that urinary VEGF may gain access to the 
bladder wall via their receptors. According to this 
evidence and the inflammation data from histologi-
cal analysis, investigating the relationship of VEGF 
proteins and their receptor/co-receptor in the abnor-
mal urothelium of patients with IC/PBS might clarify 
the role of VEGF in the pathogenesis of urothelial 
dysfunction in IC/PBS.
In previous research, some evidence has strongly 
suggested that abnormal differentiation in the IC/PBS 
urothelium with a loss of E-cadherin and altered 
differentiation markers is independent and occurs 
independently of inflammation [26]. But some results 
show a less proliferative phenotype, with increased 
expression of E-cadherin in IC/PBS. Some evidence 
showed that elevated E-cadherin may represent an 
adaptation to increased bladder permeability [18,24]. 
Our preliminary results indicated that the distribution 
of E-cadherin is different in patients with IC/PBS with 
different maximal bladder capacities (Fig. 3). There-
fore, the role of E-cadherin in the pathophysiology of 
IC/PBS is still controversial. We need more molecular 
and histological evidence to investigate the role of 
E-cadherin in IC/PBS.
Previously published results and data confirm that 
IC/PBS involves an aberrant differentiation program in 
the bladder urothelium that leads to altered synthesis 
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TUNEL (normal)
TUNEL (IC/PBS)
FITC DAPI Merge
FITC DAPI Merge
Positive control
Fig. 1 — TUNEL stain shows that the number of apoptotic cells is slightly increased in patients with IC/PBS compared 
with normal controls.
of several proteoglycans, cell adhesion and tight junc-
tion proteins, and bacterial defense molecules such as 
GP51. Therefore, replacement therapy with glycosami-
noglycans has been widely used for treatment of IC/
PBS [27]. However, further correlation of the expression 
of the proteoglycan core proteins and differentiation 
related markers with inflammation scores in IC/PBS 
bladder biopsies revealed that the abnormalities in 
urothelial differentiation and loss of barrier function 
in IC/PBS were independent of inflammation [26].
Expression of intercellular adhesion molecules 
ICAM-1, P-selectin, and E-selectin is highly positive in 
bladders with IC/PBS but not in controls. ICAM-1 binds 
to cellular adhesion molecules (CAMs), which is nec-
essary for initiation of inflammation. The results sup-
port different degrees of bladder inflammation in IC/
PBS [28]. Increased ICAM-1 intensity was found in 
IC/PBS patients. The ICAM-1 intensity was higher in 
those who responded to bladder hydrodistention plus 
hyaluronic acid instillation. By blocking the ICAM-1 
receptors, hyaluronic acid presumably alleviates the 
inflammatory process [29].
Bladders with IC/PBS showed morphological changes 
indicative of apoptosis. TUNEL staining showed apo-
ptotic cells in the microvascular endothelial cells but 
not in the endothelial cells of venules. Bladder micro-
vascular endothelial cells may play an important role 
in the pathogenesis of IC/PBS [30]. Bladder epithelial 
cells from patients with IC/PBS exhibited profoundly 
decreased proliferation, decreased expression of cy-
clic D1 and JNK and increased paracellular permeabil-
ity compared to normal urothelial cells. Experiments 
in serum-free medium showed that the proliferation 
rate of explanted bladder epithelial cells from patients 
with IC/PBS was significantly decreased compared to 
that of control cells, indicating an intrinsic abnormality 
in IC/PBS cell proliferation. This abnormality may be 
caused by APF, which induces reversible inhibition of 
HB-EGF-like growth factor production and normal blad-
der epithelial cell proliferation [31]. APF treatment 
caused significant increases in the paracellular perme-
ability of normal bladder epithelial cell monolayers and 
the attenuation of tight junctions compared to mock 
APF, similar to changes seen in IC cells. APF treatment 
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ki-67 (control)
ki-67 (IC/PBS)
FITC DAPI Merge
FITC DAPI Merge
Fig. 2 — The signal of Ki-67 in IC/PBS is dramatically reduced compared with that in normal controls. This result indicates 
that the differentiation and growth rate of urothelium in IC/PBS is abnormally decreased.
E-cadherin (MBC=800)
E-cadherin (MBC=900)
FITC DAPI Merge
FITC DAPI Merge
Fig. 3 — Immunohistochemistry study of E-cadherin shows that the distribution of E-cadherin is different in patients 
with IC/PBS with different bladder capacities.
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also decreased expression of the tight junction proteins 
zonula occludens-1 and occludin [18,32].
5. Effect of chronic inflammation on 
urothelial dysfunction
Chronic suburothelial inflammation might inhibit nor-
mal basal cell proliferation and affect apical urothelial 
function. Treatment of urothelial dysfunction cannot 
be based solely on replacement of defense glycopro-
teins in the bladder urothelium. Furthermore, bladder 
inflammation caused by intravesical irritants or in 
patients with IC/PBS leads to acute afferent nerve 
activity and to long-term plasticity that lowers the 
threshold for nociceptive and mechanoceptive affer-
ent fibers [33,34]. Chronic sensitization of afferent 
fibers might involve both peripheral and central 
mechanisms. A rise in bladder nerve growth factor in 
the muscle or urothelium initiates signals that are 
transported along the afferent nerves of the bladder 
to the dorsal root ganglion or spinal cord [35,36]. 
Based on these data, successful treatment of IC/PBS 
should aim at several targets including urothelial de-
fense defects and suburothelial inflammation.
Previous studies showed that intravesical injection 
of botulinum toxin A (BoNT-A) reduced bladder pain in 
patients with refractory IC/PBS [37,38]. Nerve growth 
factor levels in the bladder tissue are significantly in-
creased in patients with IC/PBS and decreased to the 
normal range after BoNT-A treatment [39]. Repeated 
BoNT-A injections plus hydrodistention might pro-
vide a better outcome in treating IC/PBS. If repeated 
BoNT-A injections can relieve bladder pain and in-
crease bladder capacity in responders, the result might 
provide evidence of urothelial repair and reduction 
of suburothelial inflammation in IC/PBS responders. 
Chronic suburothelial inflammation might alter uro-
thelial function and cell differentiation, and BoNT-A 
injection might reduce the inflammation and restore 
a healthy urothelium, thereby improving the clinical 
symptoms of IC/PBS.
6. Conclusion
Investigation of the relationship between chronic in-
flammation and urothelial dysfunction such as urothe-
lial apoptosis, expression of junctional protein and 
inflammatory reactions in the suburothelium of pa-
tients with IC/PBS might demonstrate the hypothesis 
that suburothelial inflammation affects urothelial 
function. Treatment of IC/PBS by surface protective 
agents without an anti-inflammatory effect might not 
adequately eradicate the pathophysiology of IC/PBS. 
Investigating changes in urothelial dysfunction and 
suburothelial inflammation at baseline and after 
BoNT-A injections can provide evidence for the exist-
ing pathophysiology of IC/PBS.
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